Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

100%

3 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 3
3(100.0%)
3Total
Phase 3(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT01709721Phase 3Completed

Safety and Efficacy Study of Hydromorphone Hydrochloride by Intrathecal Administration

Role: lead

NCT01709747Phase 3Completed

Single-arm Study to Assess the Safety of Hydromorphone Hydrochloride by Intrathecal Administration

Role: lead

NCT01520545Phase 3Completed

Safety Study of 3 mg/mL Baclofen Injection (Intrathecal) Using A Programmable Pump

Role: lead

All 3 trials loaded